Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01885078 · ClinicalTrials.gov registry record · Phase 3
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,877
- Enrollment target
NCT01885078 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 2,877 participants.
The verdict
NCT01885078, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,877 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study. The study provides 7 years of additional treatment with baricitinib.
Interventions
- DRUG Placebo
- DRUG Baricitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,877 participants |
| Start Date | 2013-06-27 |
| Est. Completion | 2020-11-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01885078
The ClinicalTrials.gov registry entry for NCT01885078 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,877 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01885078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01885078 about?
NCT01885078 is a clinical study titled "An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis". The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study. The study provides 7 years of additional treatment with baricitinib.
What is the current status of trial NCT01885078?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,877 participants. The study started on 2013-06-27. Estimated completion is 2020-11-12.
What interventions are being tested in trial NCT01885078?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).
Who is sponsoring clinical trial NCT01885078?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.